EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis

Olivia Boyer, Mélissa Ould Rabah, Evgenia Preka

Pediatric Drugs · 2024-11 · 26 (6) · 649-657

DOI: 10.1007/s40272-024-00651-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Drugs, online erschienen am 26.09.2024. Verfasst von Olivia Boyer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et l'Adulte (MARHEA), Hôpital Universitaire Necker-Enfants…. Hauptthemen laut MEDLINE: Acidosis, Renal Tubular, Potassium Citrate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Distal renal tubular acidosis (dRTA) is characterized by a primary defect in proton secretion by α-intercalated cells of the collecting duct, leading to impaired urine acidification and resulting in metabolic acidosis, hypokalemia, and hypercalciuria. Inherited forms of dRTA are currently associated with variants in five genes (SLC4A1, ATP6V1B1, ATP6V0A4, FOXI1, and WDR72), each being associated with specific extra-renal manifestations. Acquired forms can result from autoimmune diseases or drug side effects. Classical complications include nephrolithiasis, nephrocalcinosis, reduced glomerular filtration rate (GFR), bone demineralization, and growth failure. Treatment focuses on correcting the acid-base imbalance through alkali supplementation (potassium, sodium, or magnesium bicarbonate or citrate) to reduce renal disease progression and promote normal growth and mineralization. Traditional treatments (alkali and potassium supplementation) often suffer from poor adherence due to frequent day and night administrations, gastrointestinal discomfort, and unpleasant taste. A novel investigational drug, ADV7103, which contains potassium citrate and potassium bicarbonate in an extended-release formulation, has recently been approved by the European Medicine Agency (EMA) for dRTA. Recent studies support its use as a first-line treatment, given its efficacy and safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acidosis, Renal TubularPotassium CitrateHumansChildBicarbonatesPotassium CompoundsDrug Combinations

Substanzen

Potassium CitrateBicarbonatespotassium bicarbonatePotassium CompoundsDrug Combinations

Autor:innen und Institutionen

  • Néphrologie Pédiatrique, Centre de Référence des Maladies Rénales Héréditaires de l'Enfant et l'Adulte (MARHEA), Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (APHP), Institut Imagi…
  • Explorations Fonctionnelles, Hôpital Universitaire Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
  • INSERM U970, PARCC, Paris Translational Research Centre for Organ, Transplantation, Paris, France.

Zitieren

APA

Boyer, O., Ould Rabah, M., & Preka, E. (2024). Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis. Pediatric Drugs, 26(6), 649-657. https://doi.org/10.1007/s40272-024-00651-9

Vancouver

Boyer O, Ould Rabah M, Preka E. Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis. Pediatric Drugs. 2024;26(6):649-657. doi:10.1007/s40272-024-00651-9

BibTeX
@article{Boyer2024,
  author = {Boyer, Olivia and Ould Rabah, Mélissa and Preka, Evgenia},
  title = {Recent Developments in the Treatment of Pediatric Distal Renal Tubular Acidosis},
  journal = {Pediatric Drugs},
  year = {2024},
  volume = {26},
  number = {6},
  pages = {649--657},
  doi = {10.1007/s40272-024-00651-9}
}
Kostenlos starten →